Prevalence, treatment, and control of severe hyperlipidemia

Abstract

Objective To identify the prevalence, treatment, and low-density lipoprotein cholesterol (LDL-C) control of individuals with LDL-C ≥190 ​mg/dL in contemporary clinical practice. Methods We included adults (age ≥18 years) with LDL-C ≥190 ​mg/dL, at least one LDL-C level drawn from 255 health systems participating in Cerner HealthFacts database (2000–2017, n ​= ​4,623,851), and a detailed examination within Duke University Health System (DUHS, 2015–2017, n ​= ​267,710). Factors associated with LDL-C control were evaluated using multivariable logistic regression modeling. Results The cross-sectional prevalence of LDL-C ≥190 ​mg/dL was 3.0% in Cerner (n ​= ​139,539/4,623,851) and 2.9% at DUHS (n ​= ​7728/267,710); among these, rates of repeat LDL-C measurement within 13 months were low: 27.9% (n ​= ​38,960) in Cerner, 54.5% (n ​= ​4211) at DUHS. Of patients with follow-up LDL-C levels, 23.6% in Cerner had a 50% of greater reduction in LDL-C, 18.3% achieved an LDL-C <100 ​mg/dL and 2.7% ​< ​70 ​mg/dL. At DUHS, 28.4% had a 50% or greater reduction in LDL-C, 28.4% achieved an LDL-C ≤100 ​mg/dL and 4.4% achieved <70 ​mg/dL. Within DUHS, 71.6% with LDL-C ≥190 ​mg/dL were on any statin during follow-up, but only 28.5% were on a high-intensity statin. In multivariable modeling, seeing a cardiologist (Cerner odds ratio [OR] 1.56, confidence interval [CI] 1.33–1.83; DUHS OR 1.89, 95% CI 1.18–3.01) and having diabetes (Cerner OR 1.34 CI 1.23–1.46; DUHS OR 2.07, CI 1.62–2.65) increased odds of LDL-C control, defined as a ≥50% reduction in LDL-C (at Cerner) or initiation of high intensity statin (at DUHS). Prior atherosclerotic cardiovascular disease (OR 1.19, CI 1.07–1.33), hypertension (OR 1.10, CI 1.03–1.18), African American race (OR 0.79, CI 0.71–0.89), and government (vs. private) insurance (OR 0.90, CI 0.83–0.98) were associated with LDL-C control at Cerner. Female sex was associated with lower odds of appropriate therapy (OR 0.69, CI 0.59–0.81) at DUHS. Conclusions Approximately 3% of United States adults have LDL-C ≥190 ​mg/dL. Among those with very high LDL-C, rates of repeat measurement within one year were low; of those retested, only about one-fourth met guideline-recommended LDL-C treatment goals.

The Epidemiological Analysis of COVID-19 Outbreaks in Nursing Homes during the Period of Omicron Variant Predominance

“…For data validation, we double-checked the data entries for typographical errors and compared the prevalence rates of the underlying diseases with previously published data. For example, the prevalence rates of hypertension, dementia, diabetes mellitus, chronic obstructive pulmonary disease, and hyperlipidemia were similar to the previously published data worldwide [25][26][27][28][29]. We also checked for internal consistency by comparing related variables to ensure they were logically coherent.…”

Detection of synthetic lipid‐lowering adulterants in herbal products using high‐performance thin‐layer chromatography

“…Hyperlipidemia is considered one of the major risk factors causing cardiovascular diseases. Further complications of unaddressed hyperlipidemia may lead to coronary and/or periphery artery disease, cerebrovascular strokes, aneurysms, type II diabetes, hypertension, and death [2, 3]. Various modern allopathic remedies are available to manage the lipid level in the desirable range [4].…”

LOGAN-CV: A Prospective Study of a Multifaceted Intervention Targeting United States Clinicians to Improve Guideline-Based Management of Lipid-Lowering Therapy

“…A key part of implementing guideline-directed lipid lowering is testing for lipid levels in appropriate patients. A recent cross-sectional study conducted in the US revealed that the rates of repeat LDL-C measurement within 1 year were low (27.9%-54.5%), and only approximately onequarter of patients tested were below the guideline-recommended LDL-C threshold [18].…”